Fenwick represented Sema4, a patient-centered health intelligence company, in its oversubscribed Series C financing of $121 million at a post-money valuation of over $1 billion. The financing was led by funds managed by BlackRock, and included participation by new investors Deerfield Management Company and Moore Strategic Ventures, as well as Sema4’s existing investors. Sema4 was spun out of the Mount Sinai Health System in June 2017.
More information about the financing can be obtained from Sema4’s announcement.
The Fenwick transaction team included corporate partner Ethan Skerry and associates Jonathan Allan, Kristin Esannason and Joanna Xu.